Dianthus Therapeutics (DNTH) EBIT (2017 - 2025)

Dianthus Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$40.3 million for Q3 2025.

• On a quarterly basis, EBIT fell 34.74% year-over-year to -$40.3 million in Q3 2025; TTM through Sep 2025 was -$140.3 million, a 69.24% decrease from a year earlier, with the FY2024 full-year figure at -$101.9 million, down 111.45% from the prior year.
• EBIT retreated to -$40.3 million in Q3 2025 per DNTH's latest filing, from -$34.9 million in the prior quarter.
• Across five years, EBIT topped out at -$7.7 million in Q1 2023 and bottomed at -$40.3 million in Q3 2025.
• The 5-year median for EBIT is -$18.2 million (2021), against an average of -$20.7 million.
• Across the five-year window, EBIT soared 67.76% in 2023 and sank 146.34% in 2024, its largest moves.
• Year by year, EBIT stood at -$20.1 million in 2021, then soared by 46.91% to -$10.7 million in 2022, then retreated by 21.16% to -$13.0 million in 2023, then sank by 146.34% to -$31.9 million in 2024, then dropped by 26.23% to -$40.3 million in 2025.
• Per Business Quant, the three latest DNTH EBIT figures stand at -$40.3 million (Q3 2025), -$34.9 million (Q2 2025), and -$33.2 million (Q1 2025).